Singapore researchers have developed an unlimited number of pure insulin-producing cells from mouse embryonic stem cells (ESCs). These pure insulin-producing cells, which according to electron microscopy studies, have the same sub-cellular structures as the insulin-producing cells naturally found in the pancreas, were highly effective in treating diabetes in the mouse model. The transplants of pure
Full Post: Scientists develop unlimited pure insulin-producing cells from mouse embryonic stem cells
Biothera has announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August.
This arm of the trial is evaluating the combination therapy of its lead drug candidate, Imprime PGG, with Erbitux, an anti-cancer monoclonal antibody from ImClone Systems. Unlike the first trial arm, the second treatment arm does not include chemotherapy.
In the first arm of the trial, which was fully enrolled this past July, Imprime PGG was combined with Erbitux (cetuximab) and irinotecan, a chemotherapy drug, which is the standard of care for second- and third-line mCRC patients.
“We are very excited about the initial results from the first arm of our mCRC trial,” said Daniel Conners, Biothera chairman and founder. “In the second arm, we expect that patients receiving Imprime PGG and Erbitux alone can achieve positive outcomes with the horrendous side effects of irinotecan chemotherapy.”
Imprime PGG utilizes a novel mechanism of action that activates specific immune cells to kill antibody targeted cancer cells. The mobilization of a population of innate immune cells not normally involved in anti-tumor activity has the potential to dramatically enhance existing cancer monoclonal antibody therapy. Irinotecan and other chemotherapies are effective at killing cancer cells, but they also can cause serious toxicity and potentially life-threatening side effects by suppressing immune system function.
“If we can match or exceed the treatment efficacy of the Erbitux and irinotecan therapy without the corresponding toxicities associated with irinotecan, we may be able to provide an exciting treatment option for cancer patients in terms of enhanced survival and quality of life,” said Conners.
The Biothera mCRC clinical trial is an open-label, multicenter trial in Asia. In both arms, the study is evaluating the safety and efficacy of Imprime PGG at various dose levels.
http://www.biothera.com
--------------------------------------------------------------------------------------------
Related Posts:
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center. Presented today on the press program of the 2008 Chicago
Full Post: Combination of carboplatin and paclitaxel with bevacizumab and cetuximab proves safe for lung cancer treatment
Peregrine Pharmaceuticals, Inc. has announced that updated preliminary data from the first stage of its Phase II trial evaluating bavituximab in combination with docetaxel showed that 10 of 14 (71%) evaluable breast cancer patients achieved an objective tumor response according to RECIST criteria. The company also reported that patient screening has begun in the
Full Post: Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer
Centocor, Inc., has announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab. The application, filed by Centocor in late 2007, seeks approval to market ustekinumab as a subcutaneous biologic therapy for the treatment of adult patients with chronic moderate to severe plaque
Full Post: FDA issues complete response to biologics license application for ustekinumab
The combination of traditional chemotherapy agents with targeted therapies called monoclonal antibodies showed no safety concerns and improved survival in patients with advanced non-small cell lung cancer according to a study presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and the University of Chicago. The combination of bevacizumab
Full Post: Traditional chemotherapy agents with targeted therapies improves survival in advance-stage lung cancer
Biopure Corporation has announced that it has submitted to the Food and Drug Administration (FDA) an investigational new drug (IND) application to conduct a pilot phase 2 clinical trial of the company’s oxygen therapeutic Hemopure [hemoglobin glutamer - 250 (bovine)]. In the proposed trial Hemopure would be studied for use in the treatment of life-threatening
Full Post: Biopure submits IND for trial in patients with acute myeloid leukemia --------------------------------------------------------------------------------------------
